References
- Meunier F, Aoun M, Gerard M. Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind syudy of fluconazole vs. ketoconazole. Rev Infect Dis 12 Suppl 1990; 3: 364–368
- Viscoli C, Castagnola E, Fioredda F, Ciravegna B, Barigione G, Terragne A. luconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemother 1991; 35: 365–367, F
- Dupont B, Drouet E. Fluconazole in management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol 1988; 26: 67–71
- Bart-Delabesse E, Poiron P, Carlotti A, Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 1993; 31: 2933–2937
- Tioillet N, Durussel C, Biile J, Glauser M P, Chave J P. Correation between in vitro susceptibility of Candida albicans and fluconazole-resistant cropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993; 12: 911–915
- Phaffer M A, Rhine-Chalberg J, Redding S W, Smith J, Farinacci G, Fothergill A W, Rinaldi M G. Variations in fluconazole susceptibility and electrophoretic karotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994; 32: 59–64
- Millon L, Manteaux A, Reboux G, Drobacheff C, Monod M, Barale T, Michel-Briand Y. Fluconazole-resistant recurrent oral candidiasis in human immumodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994; 32: 1115–1118
- Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092–2098
- Torssander J, Morfeldt-Manson L, Biberfeld G, Karlsson A, Putkonen P-O, Wasserman J. Oral Candida albicans in HIV infection. Scand J Infect Dis 1987; 19: 291–295
- Denning D W, Hanson L H, Stevens D A. In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against Aspergillus species. Eur J Clin Microbiol Infect Dis 1990; 9: 693–697
- National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pennsylvania 1992
- Phaffer M A, Burmeister L, Bartlett M S, Rinaldi M G. Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol 1988; 26: 1437–1441
- Espinel-Ingroff A, Kerkering T M, Goldson P R, Shadomy S. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1991; 29: 1089–1094
- Marriott D JE, Jones P D, Hoy J F, Speed B R, Harkness J L. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. Med J Aust 1993; 158: 312–316
- Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, Rhine-Chalberg J, Phaller M. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994; 18: 240–242
- Hitchcock C A, Pye G W, Troke P F, Johnson E M, Warnock D W. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993; 37: 1962–1965